Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin therapy versus gliclazide for beta-cell survival in MODY3
2008-005263-34Phase 2Terminated
- Sponsor
- The Mater Foundation
- Start
- Nov 2008
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gliclazide, insulin aspart, insulin detemir in maturity-onset diabetes of the young type 3, type 2 diabetes mellitus (T2DM), sponsored by The Mater Foundation. Started Nov 2008; status: terminated.
02
Drugs
gliclazideinsulin aspartinsulin detemir
03
Conditions
maturity-onset diabetes of the young type 3type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005263-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005263-34.